Association of Obesity, Diabetes, and Alcohol Use With Liver Fibrosis Among US Adults With Hepatitis C Virus Infection

Overview

Journal JAMA Netw Open

Publisher American Medical Association

Specialty General Medicine

Date 2022 Mar 18

PMID 35302636

Authors

Alexandra L Migdal

Ram Jagannathan

Emad Qayed

Kenneth Cusi

Rozalina G McCoy

Francisco J Pasquel

Lesley S Miller

Affiliations

Soon will be listed here.

Citing Articles

Association of MASLD Phenotypes With Liver Fibrosis in Hepatitis C: The Role of Cardiometabolic Risk Factors.

Elgretli W, Shengir M, Sasson S, Ramanakumar A, Cinque F, Ballestreros L J Viral Hepat. 2025; 32(2):e70004.

PMID: 39868661 PMC: 11771651. DOI: 10.1111/jvh.70004.

Hazardous Alcohol Use and Its Effect on Direct-Acting Antiviral Therapy Initiation among People with Active Injection Drug Use and Current Hepatitis C Infection.

Karimi-Sari H, Lucas G, Zook K, Weir B, Landry M, Sherman S Viruses. 2024; 16(9).

PMID: 39339891 PMC: 11437464. DOI: 10.3390/v16091416.

Food inequity and insecurity and MASLD: burden, challenges, and interventions.

Zelber-Sagi S, Carrieri P, Pericas J, Ivancovsky-Wajcman D, Younossi Z, Lazarus J Nat Rev Gastroenterol Hepatol. 2024; 21(10):668-686.

PMID: 39075288 DOI: 10.1038/s41575-024-00959-4.

Investigating the causal association between obesity and risk of hepatocellular carcinoma and underlying mechanisms.

Chen Z, Ding C, Chen K, Gu Y, Qiu X, Li Q Sci Rep. 2024; 14(1):15717.

PMID: 38977823 PMC: 11231137. DOI: 10.1038/s41598-024-66414-1.

Impact of Direct-Acting Antiviral Therapy on Liver Fibrosis Regression among People with Chronic HCV Infection: Results from a Real-Life Cohort in Patients Who Achieved Sustained Virological Response.

Garcia-Ros A, Moran S, Nunez V, Garcia-Ros G, Ruiz G, Garcia-Solano J Medicina (Kaunas). 2023; 59(4).

PMID: 37109770 PMC: 10141631. DOI: 10.3390/medicina59040814.

References

Monto A, Alonzo J, Watson J, Grunfeld C, Wright T . Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol. Hepatology. 2002; 36(3):729-36. DOI: 10.1053/jhep.2002.35064. View

Ong J, Younossi Z, Speer C, Olano A, Gramlich T, Boparai N . Chronic hepatitis C and superimposed nonalcoholic fatty liver disease. Liver. 2001; 21(4):266-71. DOI: 10.1034/j.1600-0676.2001.021004266.x. View

Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J . Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c. J Hepatol. 2001; 34(5):730-9. DOI: 10.1016/s0168-8278(00)00097-0. View

Afsari A, Lee E, Shokrani B, Boortalary T, Sherif Z, Nouraie M . Clinical and Pathological Risk Factors Associated with Liver Fibrosis and Steatosis in African-Americans with Chronic Hepatitis C. Dig Dis Sci. 2017; 62(8):2159-2165. PMC: 5706543. DOI: 10.1007/s10620-017-4626-7. View

Papatheodoridis G, Chrysanthos N, Savvas S, Sevastianos V, Kafiri G, Petraki K . Diabetes mellitus in chronic hepatitis B and C: prevalence and potential association with the extent of liver fibrosis. J Viral Hepat. 2006; 13(5):303-10. DOI: 10.1111/j.1365-2893.2005.00677.x. View